Abraxis BioScience, Inc. (NASDAQ: ABII) today announced that multiple clinical studies of the chemotherapy agent ABRAXANE for Injectable Suspension (paclitaxel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE